EDINBURGH, Scotland--(BUSINESS WIRE)--A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm. The firm has discovered a new antibiotic compound thought to be effective against a broad spectrum of Multi-Drug Resistant bacteria including Multi-Drug Resistant Staphylococcus Aureus (MDRSA) and Multi-Drug resistant Streptococcus Pneumoniae (MDRSP), Clostridium Difficile and Enteroccocus Faecalis which are common causes of death in patients in hospital care units.
